~統合再編から世界に向けて~

福島県立医科大学 消化管外科学講座

業績

ホーム > 業績

業績集 消化管外科学講座 平成30年(2018年)

(分類は大学の業績集に準じています)

(1) 論文

①原著 (筆頭著者のイニシアル順)
1. Ando K, Suzuki Y, Kaminuma T, Yoshimoto Y, Oike T, Okonogi N, Sato H, Tamaki T, Noda SE, Mimura K, Nakano T.  Tumor-specific CD8-positive T cell-mediated antitumor immunity is implicated in the antitumor effect of local hyperthermia. Int J Hyperthermia. 35(1):226-231, 2018.
2. Aoto K, Mimura K, Okayama H, Saito M, Chida S, Noda M, Nakajima T, Saito K, Abe N, Ohki S, Ohtake T, Takenoshita S, Kono K. Immunogenic tumor cell death induced by chemotherapy in patients with breast cancer and esophageal squamous cell carcinoma. Oncol Rep. 39(1): 151-159, 2018.
3. Fujiwara Y, Saito M, Robles AI, Nishida M, Takeshita F, Watanabe M, Ochiya T, Yokota J, Kohno T, Harris CC, Tsuchiya N. A Nucleolar Stress-Specific p53-miR-101 Molecular Circuit Functions as an Intrinsic Tumor-Suppressor Network. EBioMedicine. 33: 33-48, 2018.
4. Kanke Y, Shimomura A, Saito M, Honda T, Shiraishi K, Shimada Y, Watanabe R, Yoshida H, Yoshida M, Shimizu C, Takahashi K, Totsuka H, Ogiwara H, Hirose S, Kono K, Tamura K, Okamoto A, Kinoshita T, Kato T, Kohno T. Gene aberration profile of tumors of adolescent and young adult females. Oncotarget. 29; 9(5): 6228-6237. 2017.
5. Kawamura H, Honda M, Takiguchi K, Kamiga T, Saito K, Yamazaki S, Muto A, Shiraso S, Yamashita N, Iwao T, Saji S, Kono K. Development of a prognostic nomogram for metastatic colorectal cancer patients: The study protocol of a multicenter, retrospective, observational, cohort study. Ann. Cancer Res. Ther. 26(2): 116-119, 2018.
6. Kikuchi D, Saito M, Saito K, Watanabe Y, Matsumoto Y, Kanke Y, Onozawa H, Hayase S, Sakamoto W, Ishigame T, Momma T, Ohki S, Takenoshita S. Upregulated solute carrier family 37 member 1 in colorectal cancer is associated with poor patient outcome and metastasis. Oncol Lett. 15(2): 2065-2072, 2018.
7. Lau WM, Teng E, Huang KK, Tan JW, Das K, Zang Z, Chia T, The M, Kono K, Yong WP, Shabbir A, Tay A, Phua NS, Tan P, Chan SL, So JBY. Acquired Resistance to FGFR Inhibitor in Diffuse-Type Gastric Cancer through an AKT-Independent PKC-Mediated Phosphorylation of GSK3b. Mol Cancer Ther. 17(1): 232-242, 2018.
8. Lim KS, Mimura K, Kua LF, Shiraishi K, Kono K. Implication of Highly Cytotoxic Natural Killer Cells for Esophageal Squamous Cell Carcinoma Treatment. J Immunother. 41(6): 261-273, 2018.
9. Li Z, Maeda D, Yoshida M, Umakoshi M, Nanjo H, Shiraishi K, Saito M, Kohno T, Konno H, Saito H, Minamiya Y, Goto A. The intratumoral distribution influences the prognostic impact of CD68- and CD204-positive macrophages in non-small cell lung cancer. Lung Cancer. 123: 127-135, 2018.
10. Matsumoto Y, Saito M, Saito K, Kanke Y, Watanabe Y, Onozawa H, Hayase S, Sakamoto W, Ishigame T, Momma T, Kumamoto K, Ohki S, Takenoshita S. Enhanced expression of KIF4A in colorectal cancer is associated with lymph node metastasis. Oncol Lett. 15(2): 2188-2194, 2018.
11. Minamikawa K, Shibata M, Gonda K, Ujiie D, Ashizawa M, Nakajima T, Okayama H, Sakamoto W, Saito M, Momma M, Mimura M, Ohki S, Shimura T, Ohto H, Takenoshita S, Kono K. IL-17 and VEGF are significantly associated with disease progression involving systemic inflammation in patients with gastric and colorectal cancers. Ann. Cancer Res. Ther. Vol. 25, No. 2, pp. 67-76, 2017.
12. Mimura K, Teh JL, Okayama H, Shiraishi K, Kua LF, Koh V, Smoot DT, Ashktorab H, Oike T, Suzuki Y, Fazreen Z, Asuncion BR, Shabbir A, Yong WP, So J, Soong R, Kono K. PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer. Cancer Sci. 109(1): 43-53, 2018.
13. Minamikawa K, Okumura A, Kokudo N, Kono K. Regulation on introducing process of the highly difficult new medical technologies: A survey on the current status of practice guidelines in Japan and overseas. Biosci Trends. 12(6): 560-568,2018
14. Nakajima T, Okayama H, Ashizawa M, Noda M, Aoto K, Saito M, Monma T, Ohki S, Shibata M, Takenoshita S, Kono K. Augmentation of antibody-dependent cellular cytotoxicity with defucosylated monoclonal antibodies in patients with GI-tract cancer. Oncol Lett. 15(2): 2604-2610, 2018.
15. Noda M, Okayama H, Kofunato Y, Chida S, Saito K, Tada T, Ashizawa M, Nakajima T, Aoto K, Kikuchi T, Sakamoto W, Endo H, Fujita S, Saito M, Momma T, Ohki S, Kono K. Prognostic role of FUT8 expression in relation to p53 status in stage II and III colorectal cancer. PLoS One. 13(7): e0200315, 2018.
16. Noda M, Okayama H, Tachibana K, Sakamoto W, Saito K, Thar Min AK, Ashizawa M, Nakajima T, Aoto K, Momma T, Katakura K, Ohki S, Kono K. Glycosyltransferase Gene Expression Identifies a Poor Prognostic Colorectal Cancer Subtype Associated with Mismatch Repair Deficiency and Incomplete Glycan Synthesis. Clin Cancer Res. 24(18): 4468-4481, 2018.
17. Nohara K, Yamada K, Yamada L, Hagiwara T, Igari T, Yokoi C, Soma D, Yamashita S, Dohi T, Kawamura YI. Expression of kallikrein-related peptidase 13 is associated with poor prognosis in esophageal squamous cell carcinoma. Gen Thorac Cardiovasc Surg. 66(6): 351-357, 2018.
18. Okonogi N, Suzuki Y, Sato H, Oike T, Yoshimoto Y, Mimura K, Noda SE, Okamoto M, Tamaki T, Morokoshi Y, Hasegawa S, Ohgaki H, Yokoo H, Nakano T. Combination Therapy of Intravenously Injected Microglia and Radiation Therapy Prolongs Survival in a Rat Model of Spontaneous Malignant Glioma. Int J Radiat Oncol Biol Phys.102(3): 601-608, 2018.
19. Osanai-Sasakawa A, Hosomi K, Sumitomo Y, Takizawa T, Tomura-Suruki S, Imaizumi M, Kasai N, Poh TW, Yamano K, Yong WP, Kono K, Nakamura S, Ishii T, Nakai R. An anti-ASCT2 monoclonal antibody suppresses gastric cancer growth by inducing oxidative stress and antibody dependent cellular toxicity in preclinical models. Am J Cancer Res. 8(8): 1499-1513, 2018.
20. Saito M, Goto A, Abe N, Saito K, Maeda D, Ohtake T, Murakami Y, Takenoshita S. Decreased expression of CADM1 and CADM4 are associated with advanced stage breast cancer. Oncol Lett. 15(2): 2401-2406, 2018.
21. Saito M, Saito K, Nakano H, Kikuchu T, Okayama H, Fujita S, Endo H, Sakamoto H, Momma T, Ohki S, Kono K. Annexin A1 is upregulated in p53-positive gastric cancer. Ann. Cancer Res. Ther. 26(1): 26-30, 2018.
22. Saito M, Saito K, Shiraishi K, Maeda D, Suzuki H, Minamiya Y, Kono K, Kohno T, Goto A. Identification of candidate responders for anti-PD-L1/PD-1 immunotherapy, Rova-T therapy, or EZH2 inhibitory therapy in small-cell lung cancer. Mol Clin Oncol. 8(2): 310-314, 2018.
23. Sawamura Y, Ohto H, Ikeda K, Kanno T, Suzuki Y, Gonda K, Tasaki T, Nollet K.E, Takahashi H, Aota S. Impact of prestorage leucoreduction of autologous whole blood on length of hospital stay with a subgroup analysis in bilateral hip arthroplasty. Vox Sang. 2018 Jun 20. doi: 10.1111/vox.12674.
24. Shimura T, Shibata M, Gonda K, Hayase S, Sakamoto W, Okayama H, Fujita S, Saito M, Momma T, Ohki S, Kono K. Prognostic impact of preoperative lymphocyte-to-monocyte ratio in patients with colorectal cancer with special reference to myeloid-derived suppressor cells. Fukushima J Med Sci. 64(2): 64-72, 2018.
25. Shimura T, Shibata M, Gonda K, Kofunato Y, Ishigame T, Okada R, Sato N, Kimura T, Kenjo A, Marubashi S. Prognostic impact of soluble intercellular adhesion molecule-1 in hepatocellular carcinoma. Oncol Lett. 16(5): 6013-6018, 2018.
26. Shimura T, Shibata M, Gonda K, Matsumoto Y, Nakano K, Iwadate M, Suzuki S, Suzuki S. Prognostic impact of elevated preoperative C-reactive protein on patients with differentiated thyroid carcinoma. J Surg Res. 231: 338-345, 2018.
27. Shimura T, Shibata M, Gonda K, Okayama H, Saito M, Momma T, Ohki S, Kono K. Serum transthyretin level is associated with prognosis of patients with gastric cancer. J Surg Res. 227: 145-150, 2018.
28. Shimura T, Shibata M, Kofunato Y, Okada R, Ishigame T, Kimura T, Kenjo A, Marubashi S. Clinical significance of serum transthyretin level in patients with hepatocellular carcinoma. ANZ J Surg. 88(12): 1328-1332, 2018.
29. Sundar R, Rha SY, Yamaue H, Katsuda M, Kono K, Kim HS, Kim C, Mimura K, Kua LF, Yong WP. A phase I/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer. BMC Cancer. 18(1): 332, 2018.
30. Tan YJ, Lee YT, Yeong KY, Petersen SH, Kono K, Tan SC, Oon CE. Anticancer activities of a benzimidazole compound through sirtuin inhibition in colorectal cancer. Future Med Chem. 10(17): 2039-2057, 2018.
31. Thar Min AK, Okayama H, Saito M, Ashizawa M, Aoto K, Nakajima T, Saito K, Hayase S, Sakamoto W, Tada T, Hanayama H, Saze Z, Momma T, Ohki S, Sato Y, Motoyama S, Mimura K, Kono K. Epithelial-mesenchymal transition-converted tumor cells can induce T-cell apoptosis through upregulation of programmed death ligand 1 expression in esophageal squamous cell carcinoma. Cancer Med. 7: 3321-3330, 2018.
32. Watanabe Y, Saito M, Saito K, Matsumoto Y, Kanke Y, Onozawa H, Hayase S, Sakamoto W, Ishigame T, Momma T, Ohki S, Takenoshita S. Upregulated HOXA9 expression is associated with lymph node metastasis in colorectal cancer. Oncol Lett. 15(3): 2756-2762, 2018.
②総説等
1. Kono K. Advances in cancer immunotherapy for gastroenterological malignancy. Ann Gastroenterol Surg. 2: 244-245, 2018.
2. Kono K, Mimura K, Yamada R, Ujiie D, Hayase S, Tada T, Okayama H, Thar Min AK, Shibata M, Momma T, Saze Z, Ohki S. Current status of cancer immunotherapy for esophageal squamous cell carcinoma. Esophagus. 15(Issue1): 1-9, 2018.
3. Mimura K, Yamada L, Ujiie D, Hayase S, Tada T, Hanayama H, Thar Min AK, Shibata M, Momma T, Saze Z, Ohki S, Kono K. Immunotherapy for esophageal squamous cell carcinoma : a review. Fukushima J. Med. Sci. 64(2): 46-53, 2018.
4. Okayama H, Noda M, Kono K. Aberrant glycosylation in colorectal cancer with genomic and epigenomic alterations. Oncotarget. 9(86): 35609-35610, 2018.
5. Saito M, Kono K, Kohno T. Identification of a novel therapeutic target in driver-negative non-small cell lung cancer. Transl Lung Cancer Res. 7(Suppl 3): S218-S220, 2018.
6. Saito M, Momma T, Kono K. Targeted therapy according to next generation sequencing-based panel sequencing. Fukushima J Med Sci. 64(1): 9-14, 2018.
7. Saito M, Shiraishi K, Goto A, Suzuki H, Kohno T, Kono K. Development of targeted therapy and immunotherapy for treatment of small cell lung cancer. Jpn J Clin Oncol. 48(7): 603-608, 2018.
8. Saito M, Suzuki H, Kono K, Takenoshita S, Kohno T. Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy. Surgery Today. 48(1): 1-8, 2018.
9. Shibata M, Gonda K, Shimura T, Sakurai K, Takenoshita S. SIRS, CARS and MARS in relationship to cancer cachexia and its clinical implications. Ann. Cancer Res. Ther. 26( 1): 54-59, 2018.
10. Yehya AHS, Asif M, Petersen SH, Subramaniam AV, Kono K, Majid AMSA, Oon CE. Angiogenesis: Managing the Culprits behind Tumorigenesis and Metastasis. Medicina. 54(1):8, 2018.
11.
1. 柴田昌彦, 権田憲士, 三村耕作, 河野浩二, 大戸斉, 竹之下誠一. 骨髄由来免疫細(MDSC)と腫瘍抑制. 炎症と免疫. 26(2): 15-21
2. 三村耕作. テトラマー解説. 消化器外科. 41(2): 199-201, 2018.
③症例報告
1. Azuhata T, Shibata M, Nakamura K, Kawano D, Terakado Y, Azuhata I, Sakurai A, Yamada T, Sugita K, Tomita R, Tsuyama Y, Tanjoh K, Azuhata S. A case of clinical complete response of colorectal liver metastasis following chemotherapy with S-1 and oxaliplatin (SOX) in combination with bevacizumab. Ann. Cancer Res. Ther. 26(2): 101-104, 2018.
2. Gonda K, Tachiya Y, Hatakeyama Y, Momma T, Tamaoki T, Maejima Y, Rokkaku Y, Saji S, Shimomura K, Kono K. Poland syndrome accompanied by internal iliac artery supply disruption sequence: a case report. J Med Case Rep. 12(1): 312, 2018.
3. 青砥慶太, 松本進, 井上典夫. FOLFOX で長期cCR を得た再発大腸癌の1例. 癌と化学療法. 45(13): 2258-2260, 2018
4. 氏家大輔, 小野澤寿志, 遠藤英成, 千田峻, 渡辺洋平, 岡山洋和, 斎藤勝, 門馬智之, 佐瀬善一郎, 大木進司, 金澤匡司, 河野浩二. HALSで修復した絞扼を伴う成人Bochdalek孔ヘルニア小腸嵌頓の1例. 福島医学雑誌. 68(3): 173-176, 2018.
5. 氏家大輔, 加瀬晃志, 早瀬傑, 坂本渉, 藤田正太郎, 門馬智之, 佐瀬善一郎, 大木進司, 河野浩二. 胃管癌に対する陽子線照射後の再発例に対し胃管切除を実施した1例. 癌と化学療法. 45(13): 1946-1948, 2018.
6. 大木進司, 引地拓人, 門馬智之, 渡辺晃, 中村純, 菊地眸, 山田玲央, 氏家大輔, 楡井東, 多田武志, 花山寬之, 渡辺洋平, 早瀬傑, 権田憲士, 佐瀬善一郎, 河野浩二. 十二指腸腫瘍に対する腹腔鏡内視鏡合同手術(LECS)の応用. 癌と化学療法. 45(13): 2024-2026, 2018.
7. 権田憲士, 菊池智宏, 柴田昌彦, 畠山優一, 立谷陽介, 六角裕一, 遠藤久仁, 藤田正太郎, 坂本渉, 早瀬傑, 岡山洋和, 花山寬之, 多田武志, 楡井東, 氏家大輔, 山田玲央, 佐瀬善一郎, 門馬智之, 大木進司, 河野浩二. 傍腫瘍性小脳変性症に直腸癌を合併した1例. 癌と化学療法. 45(10): 1510-1512, 2018.
8. 権田憲士, 藤田正太郎, 柴田昌彦, 畠山優一, 立谷陽介, 六角裕一, 佐瀬善一郎, 門馬智之, 大木進司, 佐治重衡, 河野浩二. 大腸癌再発症例にAfliberceptを投与しPRを得た症例. 癌と化学療法. 45(10): 1539-1542, 2018.
9. 千田峻, 加瀬晃志, 八島玲, 片方直人, 渡辺文明, 野水整, 河野浩二. 結腸癌術後にドレーン部と吻合部に同時再発した1例. 癌と化学療法. 45(13): 1883-1885, 2018.
10. 中山裕子, 井上慎吾, 三村耕作, 中澤匡男, 木村亜矢子, 大森征人, 松田啓, 市川大輔. S-1が有効であったトリプルネガティブ乳癌の1例. 癌と化学療法. 45(9): 1343-1346, 2018.
11. 藤田正太郎, 大木進司, 早瀬傑, 氏家大輔, 菊池智宏, 多田武志, 花山寬之, 岡山洋和, 坂本渉, 遠藤久仁, 齋藤元伸, 権田憲士, 佐瀬善一郎, 門馬智之, 河野浩二. 根治的化学放射線療法で完全寛解して6年後に頸部リンパ節再発した食道癌の1例. 癌と化学療法. 45(13): 1821-1823, 2018.
12. 村上祐子, 門馬智之, 立花和之進, 長塚美樹, 松嵜正實, 野水整. 神経線維腫症1型および完全内臓逆位症を伴った異時性両側乳癌の1例. 日臨外会誌. 79( 2 ): 302-307, 2018.

(2) 著書・訳書

1. 大木進司, 河野浩二. 術野の消毒. 5年でマスター消化器外科標準手術 消化器外科専門医への道: 6-9, 2018.
2. 河野浩二, 大木進司, 佐瀬善一郎, 仲野宏, 山田玲央, 氏家大輔, 楡井東, 花山寬之, 早瀬傑, 多田武志, 権田憲士, 門馬智之. 腹臥位鏡視下食道切除術-手術の定型化-. 消化器外科 手術アトラス.41(8): 1113-1123, 2018.
3. 中山裕子, 三村耕作, 河野浩二. 免疫チェックポイント阻害薬(解説/特集). 日本臨床76巻増刊8 食道癌, 474-480, 2018.

(3) 知的財産権

1. 岡山洋和, 野田勝, 河野浩二. 国際出願番号 :PCT/JP2018/032628. 発明の名称:大腸がんの予後バイオマーカー.

業績集 消化管外科学講座 平成29年(2017年)

(1) 論文

①原著(筆頭著者のイニシアル順)
1. Ando J*, Saito M*, Imai J, Ito E, Yanagisawa, Honma R, Saito K*, Tachibana K, Momma T*, Ohki S*, Ohtake T, Watanabe S, Waguri S, Kono K*,Takenoshita S. TBX19 is overexpressed in colorectal cancer and associated with lymph node metastasis. Fukushima J Med Sci. 63(3): 141-151, 2017.
2. George J, Saito M*, Tsuta K, Iwakawa R, Shiraishi K, Scheel AH, Uchida S, Watanabe SI, Nishikawa R, Noguchi M, Peifer M, Jang SJ, Petersen I, Buttner R, Harris CC, Yokota J, Thomas RK, Kohno T. (co-first author) Genomic Amplification of CD274 (PD-L1) in Small-Cell Lung Cancer. Clin Cancer Res. 23(5):1220-1226, 2017.
3. Gonda K*, Shibata M*, Ohtake T, Matsumoto Y, Tachibana K, Abe N, Ohto H, Sakurai K, Takenoshita S. Myeloid-derived suppressor cells are increased and correlated with type 2 immune responses, malnutrition, inflammation, and poor prognosis in patients with breast cancer. Oncol Lett. 14(2):1766-1774, 2017.
4. Gonda K, Shibata M, Sato Y, Washio M, Takeshita H, Shigeta H, Ogura M, Oka S, Sakuramoto S. Elevated neutrophil to lumphocyte ratio is associated with nutritional impairment, immune suppression, resistance to S-1 plus cisplatin, and poor prognosis in patients with stage IV gastric cancer. Mol Clin Oncol. 7(6): 1073-1078, 2017.
5. Goto A, Tanaka M, Yoshida M, Umakoshi M, Nanjo H, Shiraishi K, Saito M*, Kohno T, Kuriyama S, Konno H, Imai K, Saito H, Minamiya Y, Maeda D. The low expression of miR-451 predicts a worse prognosis in non-small cell lung cancer cases. PLoS One. 12(7):e0181270, 2017.
6. Hayase S*, Kumamoto K*, Saito K*, Kofunato Y, Sato Y*, Okayama H*, Miyamoto K*, Ohki S*, Takenoshita S. L?type amino acid transporter 1 expression is upregulated and associated with cellular proliferation in colorectal cancer. Oncol Lett. 14(6): 7410-7416, 2017.
7. Hayashi H, Kohno T, Ueno H, Hiraoka N, Kondo S, Saito M*, Ichikawa H, Kato M, Shibata T, Morizane C, Sakamoto T, Shimada K, Komatsu Y, Sakamoto N, Okusaka T. The number of mutations among KRAS, CDKN2A, TP53, and SMAD4 as detected using targeted deep sequencing is a useful prognostic biomarker for pancreatic cancer. Pancreas 46(3):335-340, 2017.
8. Kasai N, Sasakawa A, Hosomi K, Poh TW, Chua BL, Yong WP, So J, Chan SL, Soong R, Kono K*, Ishii T, Yamano K. Anti-tumor efficacy evaluation of a novel monoclonal antibody targeting neutral amino acid transporter ASCT2 using patient-derived xenograft mouse models of gastric cancer. Am J Transl Res. 9(7):3399-3410, 2017.
9. Kogashiwa Y, Yasuda M, Sakurai H, Nakahira M, Sano Y, Gonda K*, Ikeda T, Inoue H, Kuba K, Oba S, Ishikawa J, Enoki Y, Matsumura S, Minami K, Ebihara Y, Sugasawa M. PD-L1 Expression Confers Better Prognosis in Locally Advanced Oral Squamous Cell Carcinoma. Anticancer Res. 37(3):1417-1424, 2017.
10. Kumamoto K, Endo S, Isohata N, Nirei A*, Nemoto D, Utano K, Saito T, Togashi K. Pseudocirrhosis caused by regorafenib in an advanced rectal cancer patient with multiple liver metastases. Mol Clin Oncol. 6(1):63-66, 2017.
11. Kunisaki C, Miyata H, Konno H, Saze Z*, Hirahara N, Kikuchi H, Wakabayashi G, Gotoh M, Mori M. Modeling preoperative risk factors for potentially lethal morbidities using a nationwide Japanese web-based database of patients undergoing distal gastrectomy for gastric cancer. Gastric Cancer. 20(3):496-507, 2017.
12. Minamikawa K, Shibata M*, Gonda K*, Ujiie D*, Ashizawa M*, Nakajima T*, Okayama H*, Sakamoto W*, Saito M*, Momma T*, Mimura K* , Ohki S*, Shimura T, Ohto H, Takenoshita S, Kono K*. IL-17 and VEGF are significantly associated with disease progression involving systemic inflammation in patients with gastric and colorectal cancers. Ann. Cancer Res. Ther. 25(2):67-76, 2017.
13. Mimura K*, Kua LF, Shimasaki N, Shiraishi K, Nakajima S, Siang LK, Shabbir A, So J, Yong WP, Kono K*. Upregulation of thioredoxin-1 in activated human NK cells confers increased tolerance to oxidative stress. Cancer Immunol Immunother. 66(5):605-613, 2017.
14. Mimura K*, Teh JL, Okayama H*, Shiraishi K, Kua LF, Koh V, Smoot DT, Ashktorab H, Oike T, Suzuki Y, Fazreen Z, Asuncion BR, Shabbir A, Yong WP, So J, Soong R, Kono K*. PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer. Cancer Sci. 2018 Jan;109(1):43-53. doi: 10.1111/cas.13424. Epub 2017 Nov 18.
15. Momma T*, Okayama H*, Saitou M*, Sugeno H*, Yoshimoto N*, Takebayashi Y, Ohki S*, Takenoshita S. Expression of circadian clock genes in human colorectal adenoma and carcinoma. Oncol Lett. 14(5):5319-5325, 2017.
16. Ohkouchi C, Kumamoto K, Saito M*, Ishigame T, Suzuki SI, Takenoshita S, Harris CC. ING2, a tumor associated gene, enhances PAI1 and HSPA1A expression with HDAC1 and mSin3A through the PHD domain and C terminal. Mol Med Rep. 16(5):7367-7374, 2017.
17. Onozawa H*, Saito M*, Saito K*, Kanke Y*, Watanabe Y*, Hayase S*, Sakamoto W*, Ishigame T, Momma T*, Ohki S*, Takenoshita S. Annexin A1 is involved in resistance to 5-FU in colon cancer cells. Oncology Rep. 37(1):235-240, 2017.
18. Saito M*, Fujiwara Y, Asao T, Honda T, Shimada Y, Kanai Y, Tsuta K, Kono K*, Watanabe S, Ohe Y, Kohno T. The genomic and epigenomic landscape in thymic carcinoma. Carcinogenesis, 38(11):1084-1091, 2017.
19. Saito M*, Okayama H*, Saito K*, Ando J, Ohki S*, Ishii Y, Takenoshita S. CDX2 is involved in microRNA-related inflammatory carcinogenesis in gastric cancer. Oncol Lett. 14(5):6184-6190, 2017.
20. Sato H, Niimi A, Yasuhara T, Permata TBM, Hagiwara Y, Isono M, Nuryadi E, Sekine R, Oike T, Kakoti S, Yoshimoto Y, Held KD, Suzuki Y, Kono K*, Miyagawa K, Nakano T, Shibata A. DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells. Nat Commun. 8(1):1751, 2017
21. Sato Y, Gonda K*, Harada M, Tanisaka Y, Arai S, Mashimo Y, Iwano H, Sato H, Ryozawa S, Takahashi T, Sakuramoto S, Shibata M*. Increased neutrophil-to-lymphocyte ratio is a novel marker for nutrition, inflammation and chemotherapy outcome in patients with locally advanced and metastatic esophageal squamous cell carcinoma. Biomed Rep. 7(1):79-84, 2017.
22. Shimura T, Shibata M*, Gonda K*, Kofunato Y, Okada R, Ishigame T, Kimura T, Kenjo A, Marubashi S, Kono K*, Takenoshita S. Clinical Significance of Soluble Intercellular Adhesion Molecule-1 and Interleukin-6 in Patients with Extrahepatic Cholangiocarcinoma. J Invest Surg. 19:1-8. 2017.
23. Shimura T, Shibata M*, Gonda K*, Kofunato Y, Okada R, Ishigame T, Kimura T, Kenjo A, Kono K*, Marubashi S. Significance of Circulating Galectin-3 in Patients with Pancreatobiliary Cancer. Anticancer Res. 37(9):4979-4986, 2017.
24. Tachibana K, Saito M*, Imai J, Ito E, Yanagisawa, Honma R, Saito K, Ando J, Momma T*, Ohki S*, Ohtake T, Watanabe S, Waguri S and Takenoshita S. Clinicopathological examination on DPEP1 expression in colorectal cancer. Biomed Rep. 6(4):423-428, 2017.
25. Tachibana K, Shibata M, Gonda K, Matsumoto Y, Nakajima T, Abe N, Ohtake T, Shimura T, Ohto H, Kono K and Takenoshita S. IL-17 and vascular endothelial growth factor (VEGF) are increased and correlated to systemic inflammation, immune suppression and malnutrition in patients with breast cancer. European J of Inflammation, 20: 1-10, 2017
26. Tada T*, Honma R, Imai JI, Saze Z*, Kogure M, Marubashi S, Tasaki K, Unakami M, Ezaki J, Tamura H, Nishikawa A, Hashimoto Y, Waguri S, Watanabe S, Gotoh M. A novel gene expression scoring system for accurate diagnosis of basaloid squamous cell carcinoma of the esophagus. Int J Oncol. 51(3):877-886, 2017.
27. Zhu L, Rossi M, Cui Y, Lee RJ, Sakamoto W*, Perry NA, Urs NM, Caron MG, Gurevich VV, Godlewski G, Kunos G, Chen M, Chen W, Wess J. Hepatic β-arrestin 2 is essential for maintaining euglycemia. J Clin Invest. 127(8):2941-2945, 2017.
28. Zhu L, Almaca J, Dadi PK, Hong H, Sakamoto W*, Rossi M, Lee RJ, Vierra NC, Lu H, Cui Y, McMillin SM, Perry NA, Gurevich VV, Lee A, Kuo B, Leapman RD, Matschinsky FM, Doliba NM, Urs NM, Caron MG, Jacobson DA, Caicedo A, Wess J. β-arrestin-2 is an essential regulator of pancreatic β-cell function under physiological and pathophysiological conditions. Nat Commun. 8:14295, 2017.
1. 芦澤舞*, 岡山洋和*, Aung Kyi Thar Min*, 野田勝, 青砥慶太*, 中島隆宏*, 石亀輝英, 三村耕作*, 河野浩二*. ミスマッチ修復機構欠損を有する大腸癌におけるmicroRNAによるPD-L1制御機構. 癌と化学療法. 44(10):889-891, 2017.
2. 大木進司*, 加瀬晃志*, 千田峻*, 早瀬傑*, 藤田正太郎*, 門馬智之*, 高和正, 河野 浩二*, 大竹 徹, 竹之下 誠一. 80歳以上の高齢者大腸癌におけるリスク評価と予後の解析. 癌と化学療法. 43(12):1532-1534, 2016.
3. 志村龍男, 柴田昌彦*, 小船戸康英, 石亀輝英, 岡田良, 木村隆, 見城明, 丸橋繁, 大木進司*, 河野浩二*, 竹之下誠一. 肝胆膵癌における血中galectin-3の意義. 日本臨床外科学会雑誌 78巻4号, 633-637, 2017.
②総説等
1. Kono K*, Yong WP, Okayama H*, Shabbir A, Momma T*, Ohki S*, Takenoshita S, So J. Intraperitoneal chemotherapy for gastric cancer with peritoneal disease: experience from Singapore and Japan. Gastric Cancer. 20(Suppl 1):122-127, 2017.
1. 河野浩二*. 胃癌 化学療法. 日本外科学会雑誌. 118巻3号, 351-353, 2017.
2. 柴田昌彦、河野浩二 癌免疫カンファレンスルーム、連載の開始にあたって、消化器外科40(10): 1474-1476,2017
3. 柴田昌彦 癌免疫カンファレンスルーム、癌患者で起きている生体の変化、消化器外科40(11): 1575-1580,2017
4. 三村耕作*、河野浩二*. がんワクチンと免疫チェックポイント阻害剤. 癌と化学療法. 44(9):733-736, 2017.
5. 三村耕作*、中山裕子、中澤匡男、河野浩二*. 腫瘍微小環境の解析から診た抗PD-1/抗PD-L1抗体の適応. 癌と化学療法. 44(11):981-983, 2017.
③症例報告
1. Abe T, Nirei A*, Suzuki N, Todate Y, Azami A, Waragai M, Sato A, Takano Y, Nishino N, Sakuma H, Teranishi Y. Neuroendocrine tumor of the extrahepatic bile duct: A case report. Int J Surg Case Rep. 40:6-9, 2017.
2. Aoto K*, Shimura T, Kofunato Y, Okada R, Yashima R, Kiko Y, Takenoshita S. Acinar Cell Cystadenocarcinoma of the Pancreas. Case Rep Gastroenterol. 11(2):504-510, 2017.
1. 権田憲士*, 立谷陽介, 畠山優一, 柴田昌彦*, 河野浩二*, 六角裕一. 化学療法によりpCR が得られた直腸癌の2 症例. 癌と化学療法. 44(10):944-946, 2017.
2. 権田憲士*, 柴田昌彦*, 安田政実, 立谷陽介, 畠山優一, 河野浩二*, 六角裕一. 長期生存を認めた原発不明癌の3 症例. 癌と化学療法. 44(10):950-952, 2017.
3. 早瀬 傑*, 藤田正太郎*, 石井芳正, 竹之下誠一. 脾原発性悪性リンパ腫の2 治療例. 福島医学会雑誌. 67(2):75-80, 2017.
4. 藤田正太郎*, 大木進司*, 加瀬晃志*, 山内直人*, 千田峻*, 早瀬傑*, 坂本渉*, 門馬智之*, 高和正, 大竹 徹, 河野 浩二*, 竹之下 誠一. 腹腔鏡下幽門側胃切除術後のポートサイト再発を来した高齢者胃癌の1 例. 癌と化学療法. 43(12):1502-1504, 2016.
5. 松井田 元*, 佐瀬 善一郎*, 大須賀 文彦, 遠藤 久仁*, 多田 武志*, 後藤 満一. 腹腔鏡下に切除し得た隆起型蛋白漏出性胃癌の1例. 福島医学雑誌. 67巻2号,81-88, 2017.
6. 渡部 晶之, 佐瀬 善一郎*, 多田 武志*, 花山 寛之*, 佐藤 哲, 遠藤 久仁*, 木村 隆, 大須賀 文彦, 見城 明, 鈴木 剛, 後藤 満一. 外傷性肝外門脈損傷に対して,大伏在静脈グラフトによる門脈再建により救命しえた1例. 日本消化器外科学会雑誌. 50巻3号, 254-261, 2017.
7. 金田 晃尚*, 佐瀬 善一郎*, 多田 武志*, 花山 寛之*, 遠藤 久仁*, 後藤 満一. 食道GISTを併発したc-KIT陽性食道原発悪性黒色腫の1例. 日本臨床外科学会雑誌. 78巻9号 2027-2033, 2017.

(2) 著書・訳書

1. Shibata M, Gonda K, Takenoshita S. Chapter 14, Systemic Inflammation causing multiple clinical symptoms in gastrointestinal cancer. In Gastrointestinal Cancers vol.2 (Kumar AK and Prasad S ed) pp311-323, Nova Science Publishers, New York 2017
1. 大木進司*、佐瀬善一郎*、早瀬 傑*、花山寛之*、多田武志*、河野浩二*. 食道癌切除後胃管再建不能例における有茎空腸再建術. 手術. 71(13): 1789-1792, 2017
2. 齋藤元伸*, 河野隆志. 遺伝子異常に基づく肺腺がんのprecision medicine. 血液内科. 74(1):109-115, 2017.
3. 多田武志*, 佐瀬善一郎*, 花山寛之*, 丸橋繁, 河野浩二*, 後藤満一. 縦隔内限局型特発性食道破裂に対する経腹的胃底部縫着術. 手術. 71巻7号, 1077-1081, 2017.
4. 岡山洋和*、河野浩二*、竹之下誠一(翻訳).  デヴィータがんの分子生物学 第2版 第19章. メディカルサイエンスインターナショナル:2017/6/2

(3) 知的財産権

1. 岡山洋和*、野田勝、河野浩二*. 出願番号:特願2017-170157. 発明の名称:大腸がんの予後バイオマーカー. 2017/09

お問い合わせcontact

ご相談・ご質問などお気軽にお寄せください

公立大学法人福島県立医科大学 消化管外科学講座
〒960-1295 福島県福島市光が丘1
TEL 024-547-1259